Months after cancer drug trial, Merus agrees to be bought at 41% premiumBy Mario Cazombo / September 29, 2025 Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.
Book Review: The Financial Restructuring Tool Set August 6, 2025 / Book Reviews, Corporate Finance, Drivers of Value, Economics, Financial Statement Analysis, General
